

# Fab'entech

Immunotherapies to address situations of emergency

---

## Update: opportunities for Fab'entech in 2017

---

**Lyon, France – 18<sup>th</sup> July 2017** – Fab'entech is a privately-owned GMP-certified biopharmaceutical SME created in 2009 and headquartered in Lyon (France).

In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications.


Based on its horse F(ab')<sub>2</sub> polyclonal antibodies platform, a well-characterized technology, Fab'entech develops immunotherapies bringing specific medical response to situations of **public health emergency** like bioterrorism threats (i.e. anthrax) and emerging infectious diseases (i.e. avian influenza or Ebola). Its products are also particularly adapted to address situations of **medical emergency** such as intoxications (i.e. envenomation or drug intoxication) and severe infectious diseases (i.e. nosocomial infection).

Over the past 8 years, Fab'entech has completed the validation of its technology platform through the successful development of Fabenflu<sup>®</sup>, a product indicated for the treatment of avian influenza (H5N1) in human which has been granted orphan drug status in Australia & Europe.

However, due to the decrease in H5N1 human epidemiology over the years, no further investment has been made on Fabenflu<sup>®</sup> at this stage. Fab'entech has therefore decided to focus equity investments on the development of a core antidotes range (niche markets with low-risk & fast-track development plan, targeting bioterrorism threats and intoxications) rather than on emerging infectious diseases (volatile markets like avian influenza).

Today, the R&D pipeline of Fab'entech is composed of 2 products:

- **a candidate targeting Ebola virus** developed with the financial support of the European Commission and BPI France after having been identified by WHO as the unique therapeutic solution in Europe in 2014,
  - **and an antidote candidate in the field of bioterrorism** developed under a recent collaboration with the French army.
- 



Fab'entech's strategy is the following:

- Focus equity investments on the development of a core antidotes range leaded by the candidate developed in collaboration with the French army to generate revenues in a short period of time. Antidotes are characterized by a fast-track development plan and a limited level of risk; they address niche markets like bioterrorism threats & intoxications.
- Build a proprietary manufacturing site to secure industrial operations & know-how.
- Focus partnerships with private industrial companies on the co-development of immunotherapies targeting more valuable markets like nosocomial infections (i.e. *Staphylococcus aureus*).
- Push the Ebola candidate to the clinic in collaboration with public academic institutions to share the risk on this major public health project.

Main objectives of the company for 2017 are:

1. Move forward in the development of its 2 candidates and the creation of its manufacturing site → **programs ongoing**
2. Raise funds to finance the development of its core antidotes range (additional R&D programs to come) → **discussions ongoing**
3. Find private industrial companies to start co-developing immunotherapies targeting nosocomial infections → **discussions to be started soon**

---

Should you be interested in investing and / or collaborating with Fab'entech, or for any question you may have, please contact:

**Raphaël METROP**  
PharmD, Head of Corporate Business Development  
[raphael.metrop@fabentech.com](mailto:raphael.metrop@fabentech.com)

---

**Fab'entech S.A.**  
24, rue Jean Baldassini  
69007 LYON, France  
[www.fabentech.com](http://www.fabentech.com)

